Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth Scholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Below is a chart showing the trailing twelve month trading history for Scholar Rock Holding Corp, and highlighting in green where the $30 strike is located relative to that history: The chart ...

C AMBRIDGE, MA—Tracey Sacco, Chief Commercial Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold a portion of her holdings in the company. According to a filing with the ...

CAMBRIDGE, Mass., February 25, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug Future of Healthcategory· November 20, 2024 Scholar Rock's experimental drug achieved its main target in a ...